Mira Pharmaceuticals, Inc.
MIRA Nasdaq· Pharmaceutical Preparations
Last close · Oct 26, 2026
$0.53
KIRA · Stoqly’s AI analyst, in plain words
- Mira Pharmaceuticals, Inc. had $0.1M of revenue in fiscal 2025, down 40.3% on the year before.
- Mira Pharmaceuticals, Inc. lost $10.4M in fiscal 2025.
Market cap
—
P/E
—
Revenue
$0.1M
Net income
−$10.4M
Free cash flow
—
Operating margin
—
Mira Pharmaceuticals, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−40.3%
No. Sales fell 40.3% last year.
Does it make a profit?
−10,558.6%
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Mira Pharmaceuticals, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 31, 2026
- Legal name
- MIRA PHARMACEUTICALS, INC.
- CIK
- 0001904286
Mira Pharmaceuticals, Inc. · MIRA
Results and finances
The last 4 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Sales and profit | ||||
| Revenue | — | — | $0.2M | $0.1M |
| Revenue growth | — | — | — | −40.3% |
| Net interest income | — | — | $0.2M | $0.1M |
| Net income | −$7.1M | −$12.0M | −$7.9M | −$10.4M |
| Net margin | — | — | −4,739.1% | −10,558.6% |
| Diluted EPS | −$0.40 | −$0.85 | −$0.51 | −$1.35 |
| Cash | ||||
| Cash from operations | −$5.6M | −$4.5M | −$5.6M | −$4.7M |
| Share count change | — | −20.7% | 10.9% | — |
| Debt and strength | ||||
| Cash and short-term investments | $0.4M | $4.6M | $2.8M | $11.0M |
| Shareholders' equity | −$0.6M | $4.4M | $2.2M | $10.4M |
| Current ratio | 0.4x | 8.7x | 4.0x | 15.8x |
| Returns and quality | ||||
| Return on equity | — | −634.3% | −238.9% | −165.9% |
| Return on tangible equity | — | −273.9% | −357.0% | −307.9% |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Mira Pharmaceuticals, Inc. · MIRA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.53 a share, the company is worth —.
Source: SEC EDGAR XBRL filings (CIK 0001904286). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.